Related to Antisoma and Novartis Ditch ASA404 After Second Phase III NSCLC Trial Bombs

• Novartis Teams with Synthetic Genomics Vaccines to Develop Flu Seed Virus Banks
  
• Novartis Inks U.S. Commercialization Deal for Cepheid’s Ph+ CML Prognostic Tool
  
• Novartis Pays Incyte $50M on Start of Phase III Trial with INCB18424 for Polycythemia Vera
  
• IP-K Extends Collaborations with Sanofi-Aventis R&D and Novartis Tropical Disease Institute
  
• Asuragen and Novartis to Facilitate Standardization of BCR-ABL1 RT-qPCR Results
  
• Phase III Shows Tarceva Extends PFS in NSCLC with EGFR-Activating Mutations
  
• Safety Issues Prompt Lilly and BMS to Stop Enrollment into Phase III NSCLC Necitumumab Trial
  
• Novartis to Assess Quanterix’ Single Molecule Array Platform for Diagnostic Use
  
• Regeneron and Sanofi-Aventis Cancer Drug Misses Phase III Primary Endpoint but Meets Secondary Targets
  
• Second Phase III Study Shows Incyte and Novartis Drug Reduces Spleen Size in Myelofibrosis
  
• Amgen and Takeda’s NSCLC Drug Fails in Phase III Study
  
• Novartis Pays GW Pharm $5M Up Front for Sativex Rights in Multiple Territories
  
• Novartis and Vectura Confirm Positive Data from First Phase III Study with COPD Drug
  
• Novartis Pays Enanta $34M Up Front for Worldwide Rights to HCV NS5A Inhibitors
  
• Vectura, Novartis' COPD Therapy Succeeds in Fourth Phase III Study
  
• Nexavar Fails to Meet Primary Endpoint in Late-Stage NSCLC Study
  
• Boehringer Ingelheim’s Afatinib Extends PFS in EGFR Mutation-Positive NSCLC
  
• Novartis Pays Genmab $2M to Tap into Bispecific Antibody Technology
  
• Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral Gene Therapy
  
• Antisoma’s Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial